CFB
UTHR icon

Cullen/Frost Bankers’s United Therapeutics UTHR Stock Holding History

Cullen/Frost Bankers’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45K Hold
83
– – ﹤0.01% 890
2026
Q1 		$49.2K Sell
83
-20
-19% -$9.96K ﹤0.01% 802
2025
Q4 		$50.2K Buy
103
+100
+3,333% +$46.6K ﹤0.01% 800
2025
Q3 		$1.26K Hold
3
– – ﹤0.01% 1253
2025
Q2 		$862 Sell
3
-28
-90% -$8.37K ﹤0.01% 1250
2025
Q1 		$9.56K Buy
31
+28
+933% +$9.6K ﹤0.01% 952
2024
Q4 		$1.06K Sell
3
-156
-98% -$57.3K ﹤0.01% 1242
2024
Q3 		$57K Buy
+159
New +$53.7K ﹤0.01% 688
2023
Q1 		– Sell
-489
Closed -$136K – 1261
2022
Q4 		$136K Hold
489
– – ﹤0.01% 554
2022
Q3 		$102K Buy
489
+378
+341% +$84.5K ﹤0.01% 593
2022
Q2 		$26K Buy
+111
New +$22.6K ﹤0.01% 805

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Cullen/Frost Bankers's UTHR Position: Q2 2026 in Review

Cullen/Frost Bankers held its United Therapeutics (UTHR) position steady in Q2 2026 at 83 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #890.

Cullen/Frost Bankers first reported a position in UTHR in Q2 2022 and has held it in 11 quarters since. The position peaked at $136K in Q4 2022. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Cullen/Frost Bankers held 83 shares of United Therapeutics worth $45K as of Q2 2026.
  • Cullen/Frost Bankers left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #890 holding.
  • Cullen/Frost Bankers first reported a position in United Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Cullen/Frost Bankers's United Therapeutics position peaked at $136K in Q4 2022.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.